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Abstract
Huntington’s disease (HD) involves preferential and progressive degeneration of striatum and
other subcortical regions as well as regional cortical atrophy. It is caused by a CAG repeat expan-
sion in the Huntingtin gene, and the longer the expansion the earlier the age of onset. Atrophy
begins prior to manifest clinical signs and symptoms, and brain atrophy in premanifest expansion
carriers can be studied. We employed a diffeomorphometric pipeline to contrast subcortical
structures’ morphological properties in a control group with three disease groups representing
different phases of premanifest HD (far, intermediate, and near to onset) as defined by the
length of the CAG expansion and the participant’s age (CAG-Age-Product). A total of 1,428 mag-
netic resonance image scans from 694 participants from the PREDICT-HD cohort were used.
We found significant region-specific atrophies in all subcortical structures studied, with the esti-
mated abnormality onset time varying from structure to structure. Heterogeneous shape abnor-
malities of caudate nuclei were present in premanifest HD participants estimated furthest from
onset and putaminal shape abnormalities were present in participants intermediate to onset.
Thalamic, hippocampal, and amygdalar shape abnormalities were present in participants nearest
to onset. We assessed whether the estimated progression of subcortical pathology in premani-
fest HD tracked specific pathways. This is plausible for changes in basal ganglia circuits but prob-
ably not for changes in hippocampus and amygdala. The regional shape analyses conducted in
this study provide useful insights into the effects of HD pathology in subcortical structures.
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1 | INTRODUCTION
HD is an inherited, progressive, neurodegenerative brain disorder
caused by a CAG (polyglutamine) repeat expansion in the gene
encoding HTT protein (The Huntington’s Disease Collaborative
Research Group, 1993). Clinical manifestations of HD include progres-
sive deterioration of motor, cognitive, and emotional function
(Folstein, 1991; Kirkwood, Su, Conneally, & Foroud, 2001; Paulsen
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et al., 2001; Ross et al., 2014). Within the expanded CAG repeat range
(>35), longer repeats forecast an earlier age of onset and a slightly
more rapid rate of progression (Andrew et al., 1993; Brandt et al.,
1996; Rosenblatt et al., 2006).
A diagnosis of “manifest” HD is based on the presence of charac-
teristic extrapyramidal motor signs (Liu et al., 2015; Long et al., 2014;
Reilmann, Leavitt, & Ross, 2014). Large multicenter studies showed
that subtle motor, cognitive, and often emotional changes begin in the
“premanifest” period and progress slowly until an unequivocal diagno-
sis based on motor abnormalities is established (Epping et al., 2016;
Investigators of the Huntington Study Group PHAROS, 2016; Paulsen
et al., 2014; Tabrizi et al., 2013).
Striatal atrophy is the neuropathologic hallmark of HD. Neuroimag-
ing studies showed that atrophy of striatum and other brain regions typ-
ical of manifest HD begins many years prior to onset of manifest
disease. These studies demonstrated steady progression of atrophy
throughout the premanifest phase (Aylward et al., 2004; Aylward, 2007;
Paulsen et al., 2008; Tabrizi et al., 2009; Van den Bogaard et al., 2011;
Wolf, Vasic, Schonfeldt-Lecuona, Landwehrmeyer, & Ecker, 2007). The
striatal complex, particularly the caudate and putamen, is affected the
earliest (Aylward, 2007; Paulsen et al., 2008; Tabrizi et al., 2009) and
exhibits the greatest atrophy (De la Monte, Vonsattel, & Richardson,
1988; Lange, Thorner, Hopf, & Schroder, 1976). The globus pallidus is
also affected relatively early (De la Monte et al., 1988; Douaud et al.,
2006; Faria et al., 2016; Van den Bogaard et al., 2011; Younes,
Ratnanather, et al., 2014b). In addition to these basal ganglia structures,
abnormalities in other subcortical structures such as the thalamus (De la
Monte et al., 1988; Douaud et al., 2006; Faria et al., 2016; Van den
Bogaard et al., 2011) and the hippocampus (Faria et al., 2016; Van den
Bogaard et al., 2011) were detected, although with milder degrees of
abnormality. Atrophy was also observed in the cerebral cortex and sub-
cortical white matter (Bohanna , Georgiou-Karistianis, Hannan, & Egan,
2008; Douaud et al., 2006; Rub et al., 2016).
Among subcortical structures, the amygdala received relatively lit-
tle attention in HD. Irritability, disinhibition and apathy are important
features of HD-related emotional changes (Kloppel et al., 2010) and
are plausibly related to amygdala dysfunction (Mason et al., 2015; Van
den Stock et al., 2015).
The caudate, putamen, thalamus, hippocampus, and amygdala are
all comprised of multiple, functionally distinguishable, subregions (Ball
et al., 2007; Behrens et al., 2003; Fukutani et al., 1995; Gamer,
Zurowski, & Buchel, 2010; Morris, Buchel, & Dolan, 2001; Small, Nava,
Perera, Delapaz, & Stern, 2000; West, Kawas, Stewart, Rudow, &
Troncoso, 2004). These subregions exhibit differential susceptibilities to
neurodegenerative pathologies. We showed that distinct subregions of
the amygdala and the hippocampus were affected differently, in terms
of atrophy degree and rates of atrophy, by Alzheimer’s disease
(AD) (Tang et al., 2014; Tang, Holland, Dale, Younes, Miller, et al., 2015),
and distinct subregions of the basal ganglia were also affected differ-
ently in HD (Younes, Ratnanather, et al., 2014b). With the aid of shape
analysis methods, it is possible to understand how the pathology of HD
affects subregions of these subcortical structures. The identification of
subregional abnormalities may be useful in delineating circuit abnormali-
ties underlying important clinical features of HD.
Clinical features of HD are often attributed to the disruption of
circuits interconnecting the striatum and other subcortical structures
with the cerebral cortex. The basal ganglia are generally conceptual-
ized as key nodes in functionally specialized and partly anatomically
segregated parallel cortico-basal ganglionic-thalamocortical circuits
(Alexander, DeLong, & Strick, 1986). To a considerable extent, these
circuits reflect the functional organization of the cortex. A basic fea-
ture of basal ganglia circuitry organization is the topographic organiza-
tion of corticostriate projections (Haber & Knutson, 2010; Haber,
2016; Kemp & Powell, 1970; Ratnanather et al., 2013). While there is
some overlap of corticostriate projections (Selemon & Goldman-Rakic,
1985; Yeterian & Pandya, 1993), the mapping of cortical functional
domains onto striatal subregions is an important feature of striatal
organization and preserved to some extent throughout the parallel
cortico-basal ganglionic–thalamocortical circuits. Longitudinal assess-
ment of changes in striatal subregions would be useful for under-
standing the basis for specific clinical features of HD.
There are additional reasons to assess the longitudinal evolution
of atrophy of the striatal complex and other subcortical structures.
Identification of patterns of circuit-related degeneration may be useful
in assessing proposed noncell autonomous mechanisms of pathogene-
sis such as prion-like spread of proteinopathy (Pecho-Vrieseling et al.,
2014; Ross et al., 2014). Clinical trials of disease-modifying therapies
in premanifest HD cannot be performed with conventional clinical
outcome measures. Magnetic resonance imaging (MRI) based mor-
phometry measures are plausible surrogate outcome measures for
disease-modifying trials. Understanding the trajectory of morphomet-
ric changes in the premanifest phase of HD is critical to the develop-
ment of useful surrogate markers.
In this study, we investigate the shape morphometry of six
subcortical structures (caudate, putamen, globus pallidus, thalamus,
hippocampus, and amygdala) in both hemispheres in HD participants
during premanifest phases. Participants were stratified into those far
from, intermediate to, and close to onset of manifest disease. We
further investigate shape morphometry changes in subregions with
the goal of identifying possible specific circuit related patterns
involved in the pathology of premanifest HD.
2 | MATERIALS AND METHODS
2.1 | PREDICT-HD
The dataset used in this study is part of the PREDICT-HD study
(Paulsen et al., 2006, 2008, 2014) (https://www.predict-hd.net/)
where all enrolled participants were at risk of HD and had previously
received elective predictive genetic testing. Participants labeled as
premanifest HD are those found to be “gene expanded,” possessing
HTT CAG repeats ≥36 but not exhibiting the motor criteria consistent
with manifest HD (Reilmann et al., 2014; The Huntington’s Disease
Collaborative Research Group, 1993). Premanifest HD participants in
PREDICT-HD were classified with standard subdivision criteria into
three subgroups (see below); far from manifest disease onset (low-
CAP), intermediate to manifest disease onset (mid-CAP), and near to
manifest disease onset (high-CAP). The control group was defined as
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participants possessing CAG repeats ≤30. Participants in PREDICT-
HD were recruited from 32 sites across the United States, Canada,
Europe, and Australia. Participants received longitudinal study visits
consisting of neurological motor examinations, standardized cognitive
assessments, brain MRIs, psychiatric and functional rating scales, and
blood testing for genetic and biochemical analyses. Informed written
consent was obtained from all participants prior to participation.
2.2 | Subgroup definition
A useful measure of the degree of exposure to expanded CAG repeats
is the “CAG-Age-Product” or “CAP” score (“age × (CAG − L)”), where
“age” is the age of the participant at time of measurement, “CAG” is
the participant’s number of CAG repeats, and “L” is a constant close to
the threshold for a repeat count suggestive of HD (Penney, Vonsattel,
MacDonald, Gusella, & Myers, 1997). In a commonly used formula-
tion, “L” is taken to be equal to 33.66 (Zhang et al., 2011). Higher CAP
scores predict increasing proximity of manifest HD. In the premanifest
population, CAP scores can be conveniently categorized into three
groups—low CAP score group (CAP < 290), medium CAP score group
(290 ≤ CAP ≤ 368), and high CAP score group (CAP > 368).
2.3 | Participants
A total of 649 participants (168 control and 481 premanifest HD) par-
ticipated in this study, 319 of whom received two or more sequential
MR scans with the remaining 330 receiving a single scan. Demo-
graphics at the time of the baseline scans for the control group and
the three premanifest HD groups are presented in Table 1. In this lon-
gitudinal dataset, the total number of available scans varies from
participant to participant and a summary of the sequential scans as
well as the inter-scan interval information for each of the four groups
(control, low-CAP, mid-CAP, and high-CAP) is listed in Supporting
Information Table S1.
2.4 | MRI data
High resolution, T1-weighted, 3D-volume MPRAGE images were used
in this study. Given that the PREDICT-HD study was both multi-
centered and longitudinal in nature, implementation of the standard-
ized image acquisition protocol was heterogeneous secondary to
multiple vendors (GE, Phillips, and Siemens) and different field
strengths (1.5 and 3 Tesla), and culminated in more than 20 variations
in MR acquisition. Details of the acquisition information can be found
in previous PREDICT-HD studies (Harrington et al., 2016; Misiura
et al., 2017). Our study data is comprised of MPRAGE data from 3 T
scanners at 21 collection sites. Detailed demographic information for
data acquired from each site is summarized in Supporting Information
Table S2.
2.5 | Automated structure segmentation
Twelve subcortical structures (caudate, putamen, globus pallidus,
thalamus, hippocampus, and amygdala; left and right of each) were
extracted from each T1-weighted image using a fully automated
structure segmentation pipeline (Tang, Crocetti, et al., 2015) consist-
ing of two steps, skull-stripping and brain structure segmentation. The
underlying theoretical basis of this approach is multi-atlas likelihood-
fusion (MALF) in the framework of a random deformable template
model (Tang et al., 2013). This segmentation pipeline has been tested
and validated on a number of datasets with relevance to various brain
structures including the subcortical structures (Liang et al., 2015;
Tang, Crocetti, et al., 2015).
2.6 | Shape processing
Shape-based diffeomorphometric analysis is initiated by a creation of
triangulated surfaces to contour the boundary of each segmented
structure (Tang et al., 2018), as applied previously to other neurode-
generative disorders (Tang et al., 2014; Tang, Holland, Dale, Younes, &
Miller, 2015; Tang, Holland, Dale, Younes, Miller, et al., 2015). Each
bounding surface was created by deforming a triangulated model sur-
face for the corresponding subcortical structure of interest. The
12 model surfaces were created manually to ensure sufficient
smoothness and correct anatomical topology (e.g., no holes). Large
deformation diffeomorphic metric mapping (LDDMM) was employed
to deform the model surfaces, resulting in close approximations to the
contouring surfaces of the segmented volumes. These resultant trian-
gulated surfaces are the “target shapes” whose diffeomorphometrics
were analyzed subsequently.
In shape-based diffeomorphometry, we analyzed the vertex-wise
local surface areas of target shapes via connecting a common
template shape to those target shapes for each of 12 subcortical
structures diffeomorphically. The common template shape of each
structure was generated from the collection of target shapes
extracted from all baseline scans using a Bayesian template estimation
algorithm (Ma, Miller, & Younes, 2010). A population-centered tem-
plate surface avoids potential statistical bias and allows for a more
accurate mapping between the template surface and each target
surface as compared with using an arbitrary single template surface.
For each structure of interest, a target-specific diffeomorphism,
as generated by an LDDMM-surface mapping (Vaillant & Glaunes,
2005), was used to carry the common template surface to each target
surface. From each of these diffeomorphisms, a vertex-based scalar
field was subsequently calculated; the log-determinant of the Jacobian
of the diffeomorphism. This scalar field, or deformation marker, quan-
tified the factor by which the diffeomorphism expands or shrinks the
vertex-based localized surface area in the target relative to the tem-
plate in a logarithmic scale; that is, a positive value corresponds to a
localized surface area expansion of the target surface relative to the
TABLE 1 Demographic information and CAP scores of the baseline




Control 168 62/106 47.63  12.01 NA
Low-CAP 124 31/93 33.35  9.20 232.11  42.75
[79.06–287.00]
Mid-CAP 150 46/104 42.36  10.58 332.28  23.92
[287.76–367.05]
High-CAP 207 85/122 49.17  10.79 446.50  73.83
[367.3–1,013.81]
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template while a negative value suggests a localized surface area con-
traction. The deformation marker was compared between the control
group and each of the three CAP groups for each of the 12 subcortical
structures.
2.7 | Statistical analysis
For cross-sectional comparisons of the vertex-based diffeomorpho-
metrics of each subcortical structure of interest, we utilized the statis-
tical model described in our previous work (Miller et al., 2013;
Younes, Ratnanather, et al., 2014b),
ykj sð Þ¼ αk + βkg sð Þ+
X
cov
αcovXcov sð Þ+ εkj sð Þ, ð1Þ
where, ykj (s) is the deformation marker for the jth scan of participant s at
vertex k on the template surface, g(s) is a binary group variable such that
g(s) = 0 if participant s belongs to the control group and g(s) = 1 if it
belongs to a CAP group (Low, Mid, or High), Xcov(s) denotes the covariate
information of participant s included in the analysis (sex and intracranial
volume), and εkj (s) represents the random noise. A linear mixed-effects
model is used to model the noise structure as a sum of two
distinct Gaussian processes, εkj (s) = ηk (s) + ζkj (s), with ηk sð ÞN 0,ρσ2k
 
and ζkj sð ÞN 0,σ2k
 
.
The parameters αk,βk,αcov,σ2k ,k¼1,2,…
 
and ρ of our statistical
model were obtained from maximum-likelihood estimation. To check
whether there is any group difference at vertex k, we tested the null
hypothesis H0k : βk ¼0 against the general hypothesis H1k : βk 6¼0, with
the complete null hypothesis being H0k : βk ¼0 simultaneously for all
k. Since there are many vertices on each template surface, multiple
comparison correction was performed by controlling the family-wise
error rate (FWER) at a level of 0.05. The statistical significance of
group differences was quantified by p values obtained from Fisher’s
method of randomization; a nonparametric permutation test was con-
ducted by randomizing the model’s residuals. More in-depth discus-
sion of the statistical analysis can be found in Younes, Albert, Miller,
and BIOCARD Research Team (2014a).
Furthermore, we tested whether there is any interaction between
the disease pathology and the aging effect via the following statistical
model
ykj sð Þ¼ αk + βkg sð Þ+ β
0
kg sð ÞΔtj sð Þ+
X
cov
αcovXcov sð Þ+ εkj sð Þ, ð2Þ
where, Δtj(s) denotes the age difference between the jth scan of par-
ticipant s and its baseline scan, with the null hypothesis being β
0
k ¼0.
Please note the aforementioned two tests were conducted sequen-
tially; the second test was performed only when the null hypothesis
was rejected in the first one. In addition to analyzing the shape
characteristics, we performed volumetric analyses using the same
statistical models, without any need to correct for multiple compari-
sons when evaluating the statistical significance of a group difference.
2.8 | Template surface partition
The amygdala, hippocampus, and thalamus consist of multiple subre-
gions, defined on the basis of cytoarchitecture, connectivity, and
function. The striatum is more cytoarchitecturally uniform, but as
described above, has subregions defined by the pattern of cortical
afferents. We divided our hippocampal shapes into four subregions,
CA1, CA2, CA3/DG, and subiculum. Amygdalar shapes were subdi-
vided into basolateral, basomedial, centromedial, and lateral nucleus
using an approach described previously (Tang et al., 2014; Tang,
Holland, Dale, Younes, Miller, et al., 2015). This published procedure
on sub-segmenting the hippocampus and the amygdala was adopted
to transfer connectivity-based subdivision segmentations to surface
sub-divisions for the bilateral thalamus, caudate, and putamen.
For the thalamus, we used a seven-subregion division based on
an atlas using cortical connectivity to define subregions (Behrens
et al., 2003). The thalamic subregions were assigned connections to
cortical regions of the cortex according to the most likely DTI tracto-
graphy. The seven thalamic subregions are defined as those con-
nected to the primary motor cortex, sensory cortex, occipital cortex,
pre-frontal cortex, pre-motor cortex, posterior parietal cortex, and
temporal cortex (Behrens et al., 2003). The striatum was similarly sub-
divided into seven subregions based on the same probabilistic connec-
tivity algorithm. The seven subregions were those connected to
limbic, executive, rostral-motor, caudal-motor, parietal, occipital, and
temporal cortical zones (Tziortzi et al., 2014). In order to obtain the
sub-segmented putamen and caudate, we separated the striatum into
those two structures manually, ensuring both accuracy and smooth-
ness of the structural boundaries, and projected the striatal subdivi-
sions onto these two structures. The putaminal parcellation included
subdivisions from all seven subregions of the striatum partition while
caudate parcellation did not include a subregion connecting to the
occipital cortex. The occipital cortex projects to the caudate tail,
which is not identified in this analysis. For the globus pallidus, such a
template that had been divided into multiple subregions is not
available. As such, we did not conduct subregional shape analysis of
the globus pallidus.
In Supporting Information Table S3, we tabulate the ratio of the
surface area of each subregion to the entire surface area for both the
pre-defined atlases and our study-specific templates.
3 | RESULTS
3.1 | Volume analysis
The p-values obtained from comparing the volumes of each structure
between the control group and each of the three premanifest HD
groups using the first statistical model are tabulated in Table 2, with
the corresponding estimated group differences listed in Table 3. The
mean and standard deviations of the volumetric measurements of
each structure of interest for each of the four groups, restricted to
only baseline scans, are also listed in Table 3.
From the first test, significant volumetric reductions were
detected in the bilateral caudate and putamen in all three premanifest
HD groups (low-CAP, mid-CAP, and high-CAP). The degree of reduc-
tion increased with increasing CAP scores (low-CAP < mid-CAP <
high-CAP). For the globus pallidus and amygdala, in both hemispheres,
significant volumetric reductions were observed in the mid-CAP and
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high-CAP groups but not the low-CAP group. For the bilateral thala-
mus, significant volumetric reductions were only found in the high-
CAP group. And for the bilateral hippocampus, no significant group
differences were detected in all three volumetric comparisons.
For all structures exhibiting significant volumetric differences in
the first test (Equation (1)), we did not observe any significant interac-
tion effects between the clinical status and the aging effect from our
second hypothesis testing (Equation (2)).
3.2 | Shape analysis
The overall p-values obtained from comparing the shape characteris-
tics of all structures of interest between the control group and each of
the three premanifest HD groups using the first statistical model are
also tabulated in Table 2. The vertex-based shape findings of all the
six structures, namely the bilateral caudate, putamen, globus pallidus,
thalamus, amygdala, and hippocampus, are, respectively, presented in
Figures 1–6. It is worth noting that, in each figure, only vertices the
statistical significance of which had survived the FWER correction at
a level of 0.05 are highlighted. For vertices with no significant group
shape difference, the percentages of change were shown as 0%.
Being consistent with our volume findings, significant surface
atrophy was detected in the bilateral caudate and putamen in all three
HD groups, and in the bilateral globus pallidus in the mid-CAP and
high-CAP groups but not the low-CAP group. For the left thalamus,
significant surface atrophy was observed in the mid-CAP and high-
CAP groups whereas for the right thalamus only in the high-CAP
group. For the amygdala and hippocampus in the left hemisphere, sig-
nificant surface atrophy was detected in all three disease groups
whereas for those two structures in the right hemisphere, significant
surface atrophy was detected only in the mid-CAP and high-CAP
groups. As indicated by the p-values listed in Table 2, the shape
TABLE 2 The structure-specific p-values obtained from the first test
C vs. L C vs. M C vs. H
Volume Shape Volume Shape Volume Shape
Lcaud <1.00E-05 1.00E-04 <1.00E-05 <1.00E-05 <1.00E-05 <1.00E-05
Rcaud 4.00E-04 <1.00E-05 <1.00E-05 <1.00E-05 <1.00E-05 <1.00E-05
Lpal 7.48E-01 2.87E-01 <1.00E-05 <1.00E-05 <1.00E-05 <1.00E-05
Rpal 8.90E-01 5.23E-02 <1.00E-05 <1.00E-05 <1.00E-05 <1.00E-05
Lput 1.26E-02 5.30E-03 <1.00E-05 <1.00E-05 <1.00E-05 <1.00E-05
Rput 2.07E-02 <1.00E-05 <1.00E-05 <1.00E-05 <1.00E-05 <1.00E-05
Ltha 1.18E-01 2.10E-01 3.71E-01 9.30E-03 <1.00E-05 <1.00E-05
Rtha 9.90E-02 2.40E-01 5.96E-01 2.96E-01 <1.00E-05 <1.00E-05
Lam 4.40E-01 2.30E-02 2.26E-02 5.90E-03 2.00E-04 <1.00E-05
Ram 4.62E-01 1.57E-01 1.45E-02 2.00E-04 <1.00E-05 <1.00E-05
Lhi 8.46E-01 2.29E-02 5.99E-01 2.00E-04 5.46E-01 <1.00E-05
Rhi 4.10E-01 1.83E-01 1.25E-01 1.00E-04 7.90E-02 1.00E-03
L = Low-CAP; M = Mid-CAP; H = High-CAP. Keys: Lcaud, Left caudate; Rcaud, Right caudate; Lpal, Left globus pallidus; Rpal, Right globus pallidus; Ltha,
Left thalamus; Rtha, Right thalamus; lam, Left amygdala; ram, Right amygdala; Lhi, Left hippocampus; Rhi, Right hippocampus.
TABLE 3 The mean and standard deviations of the volumetric measurements (in mm3) of each structure of interest for each of the four groups
(baseline scans only), and the volumetric group differences (in mm3) estimated from the first test (a positive value indicates volumetric reductions
in the latter group relative to the former one)
Baseline statistics Group differences
Control Low-CAP Mid-CAP High-CAP C vs. L C vs. M C vs. H
Lcaud 3,952.65  534.48 3,714.66  524.17 3,533.90  487.70 3,138.98  571.29 225.81 451.81 779.79
Rcaud 3,728.02  499.55 3,529.84  503.44 3,309.71  473.43 2,912.90  538.40 192.90 455.14 784.27
Lpal 1,305.46  153.70 1,288.53  152.05 1,198.36  168.40 1,076.85  162.59 / 97.36 216.47
Rpal 1,298.83  156.81 1,274.17  160.28 1,188.64  172.32 1,068.10  168.32 / 92.22 218.74
Lput 4,105.35  461.96 3,961.44  465.68 3,605.25  443.01 3,158.69  526.64 113.49 473.25 912.76
Rput 4,238.89  484.34 4,098.34  493.42 3,742.15  498.44 3,257.29  572.74 102.90 476.36 935.05
Ltha 7,024.22  709.71 7,102.89  705.16 6,981.40  730.52 6,631.25  736.42 / / 380.82
Rtha 6,832.43  677.26 6,925.67  677.63 6,825.56  716.10 6,470.76  722.03 / / 377.47
Lam 1,231.34  145.98 1,193.19  139.60 1,194.56  138.41 1,181.56  148.73 / 27.40 39.89
Ram 1,166.79  134.28 1,126.27  136.42 1,128.02  131.44 1,111.02  137.31 / 27.91 50.63
Lhi 2,908.86  287.06 2,867.93  305.94 2,879.17  300.44 2,886.41  312.08 / / /
Rhi 2,984.97  297.12 2,920.60  326.77 2,935.21  301.00 2,939.64  309.99 / / /
L = Low-CAP; M = Mid-CAP; H = High-CAP. Keys: Lcaud, Left caudate; Rcaud, Right caudate; Lpal, Left globus pallidus; Rpal, Right globus pallidus; Ltha,
Left thalamus; Rtha, Right thalamus; lam, Left amygdala; ram, Right amygdala; Lhi, Left hippocampus; Rhi, Right hippocampus. A symbol “/” denotes no
significant group difference.
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FIGURE 1 Shape analysis results for the caudate. Statistically significant group comparison results between the control group and each of the
three premanifest HD groups (L: Low-CAP, M: Mid-CAP, H: High-CAP) for the caudate shape in each hemisphere as well the corresponding
subregion definitions. The color bar represents the percentage of atrophy at a specific vertex in the disease group relative to the control group.
The bottom panel illustrates the seven subregions of the bilateral caudate. Two views (left: Lateral, right: Medial) are presented for each case
[Color figure can be viewed at wileyonlinelibrary.com]
FIGURE 2 Shape analysis results for the putamen. Statistically significant group comparison results between the control group and each of the
three premanifest HD groups (L: Low-CAP, M: Mid-CAP, H: High-CAP) for the putamen shape in each hemisphere as well the corresponding
subregion definitions. The color bar represents the percentage of atrophy at a specific vertex in the disease group relative to the control group.
The bottom panel illustrates the seven subregions of the bilateral putamen. Two views (left: Lateral, right: Medial) are presented for each case
[Color figure can be viewed at wileyonlinelibrary.com]
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characteristics are more sensitive to the neurodegeneration in pre-
manifest HD than the volume measurements.
From the first test, we found significant caudate atrophy bilater-
ally in all three premanifest HD groups (low-CAP, mid-CAP, and high-
CAP). As illustrated in Figure 1 and Table 4, the magnitudes of atrophy
and the area of the atrophy regions increased with increasing CAP
scores (low-CAP < mid-CAP < high-CAP). Based on visual inspections
of the results in Figure 1 and the quantitative results provided in
Table 5, the greatest degree of atrophy and the largest areas of atro-
phy in all three groups were found in two subregions connected to
the limbic and executive cortices. Because of prominent shape change
in vertices belonging to the subregion connected to executive cortex
in low-CAP, it indicates that this subregion atrophies the earliest.
The putamen exhibited significant, regionally specific atrophy in
all three premanifest HD groups, though changing vertices in the low-
CAP group were sparse. As demonstrated in Figure 2 and Table 4,
FIGURE 3 Shape analysis results for the globus pallidus. Statistically significant group comparison results between the control group and each of
the three premanifest HD groups (L: Low-CAP, M: Mid-CAP, H: High-CAP) for the globus pallidus shape in each hemisphere. The color bar
represents the percentage of atrophy at a specific vertex in the disease group relative to the control group. Two views (left: Lateral, right: Medial)
are presented for each case [Color figure can be viewed at wileyonlinelibrary.com]
FIGURE 4 Shape analysis results for the thalamus. Statistically significant group comparison results between the control group and each of the
three premanifest HD groups (L: Low-CAP, M: Mid-CAP, H: High-CAP) for the thalamus shape in each hemisphere as well the corresponding
subregion definitions. The color bar represents the percentage of atrophy at a specific vertex in the disease group relative to the control group.
The bottom panel illustrates the seven subregions of the bilateral thalamus. Two views (left: Lateral, right: Medial) are presented for each case
[Color figure can be viewed at wileyonlinelibrary.com]
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significant atrophy was detected across more than 90% of the whole
putamen surfaces in both hemispheres in the mid-CAP group and the
entire surfaces in the high-CAP group. Prominent atrophy involved
vertices belonging to multiple subregions, including those connected
to limbic, executive, rostral motor, and parietal cortices (Figure 2 and
Table 6).
For the globus pallidus (Figure 3 and Table 4), significant shape
abnormalities were detected in the mid-CAP and high-CAP groups.
Interpretation of pallidal atrophy is complicated by the fact that the
globus pallidus has a relatively low density of neurons with many stria-
tal neuron terminals and fibers of passage. Pallidal atrophy likely
reflects both a loss of intrinsic neurons and striatal afferent terminals.
FIGURE 5 Shape analysis results for the amygdala. Statistically significant group comparison results between the control group and each of the
three premanifest HD groups (L: Low-CAP, M: Mid-CAP, H: High-CAP) for the amygdala shape in each hemisphere as well the corresponding
subregion definitions. The color bar represents the percentage of atrophy at a specific vertex in the disease group relative to the control group.
The rightmost panel illustrates the four subregions of the bilateral amygdala. Two views (left: Dorsal, right: Ventral) are presented for each case
[Color figure can be viewed at wileyonlinelibrary.com]
FIGURE 6 Shape analysis results for the hippocampus. Statistically significant group comparison results between the control group and each of
the three premanifest HD groups (L: Low-CAP, M: Mid-CAP, H: High-CAP) for the hippocampus shape in each hemisphere as well the
corresponding subregion definitions. The color bar represents the percentage of atrophy at a specific vertex in the disease group relative to the
control group. The rightmost panel illustrates the four subregions of the bilateral hippocampus. Two views (left: Dorsal, right: Ventral) are
presented for each case [Color figure can be viewed at wileyonlinelibrary.com]
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There were no significant shape abnormalities in the left thalamus
in the low-CAP group, but significant atrophy was detected in both
the mid-CAP and the high-CAP groups (Figure 4). For the right thala-
mus, shape abnormalities were only detected in the high-CAP group
(Figure 4). Regarding subregions, affected vertices were found in
every subregion, with a majority associated with subregions con-
nected to the pre-frontal and temporal cortices (Figure 4 and Table 7).
The hippocampus and the amygdala showed less dramatic and
less widespread shape abnormalities when compared with the caudate
and putamen (Table 4). As shown in Table 2 and Figures 5 and 6, for
the two structures in the left hemisphere, all three premanifest HD
groups experienced significant shape atrophies, whereas only mid-
CAP and high-CAP abnormalities were detected as being significant
for the corresponding right structures. For the amygdala, according to
Figure 5 and Table 8, vertices belonging to the centromedial subregion
atrophied the earliest and exhibited the most prominent deformations.
In high-CAP participants, atrophic vertices belonged also to the baso-
lateral and basomedial subregions and a small region of the lateral
nucleus. For the hippocampus of both hemispheres (Figure 6 and
Table 9), unequivocal atrophy was present in mid-CAP participants at
vertices belonging to the CA2 subregion. In high-CAP participants,
atrophy was found in all hippocampal subregions—CA1, CA2,
CA3/DG, and subiculum. The mostly affected subregion in high-CAP
participants was CA3/DG, consistent across both hemispheres. In the
left hippocampus, vertices belonging to CA2 were the next most atro-
phied subregion whereas vertices belonging to CA1 were the second
mostly affected in the right hippocampus.
Based on visual examinations of Figures 1–6 and the quantitative
results reported in Table 3, across all six subcortical structures, stria-
tum (caudate and putamen) are affected in low-CAP participants with
TABLE 4 The mean and standard deviations of the degrees of surface atrophy and the area (in mm2) of the vertices exhibiting significant atrophy
and the area ratio (in %) of the vertices exhibiting significant atrophy to the entire structure surface obtained from the first test
Atrophy degree Atrophy area
C vs. L C vs. M C vs. H C vs.L C vs. M C vs. H
Lcaud 5.09%  0.94% 7.00%  1.62% 11.15%  4.36% (663.93) 34.13% (1,688.02) 86.77% (1,582.90) 81.36%
Rcaud 4.64%  0.60% 7.60%  1.95% 12.17%  4.69% (450.17) 23.95% (1,695.37) 90.21% (1,677.72) 89.27%
Lpal / 4.47%  0.91% 9.48%  2.51% / (631.87) 87.15% (725.02) 100%
Rpal / 4.63%  0.96% 10.01%  2.45% / (588.85) 82.14% (716.93) 100%
Lput 3.37%  0.83% 6.38%  1.39% 12.27%  2.80% (38.67) 2.23% (1,601.79) 92.42% (1,733.08) 100%
Rput 3.92%  0.55% 6.24%  1.57% 12.06%  2.94% (92.47) 5.17% (1,703.50) 95.33% (1,786.99) 100%
Ltha / 4.01%  0.32% 6.13%  2.22% / (42.86) 2.12% (1,074.23) 53.03%
Rtha / / 6.18%  2.01% / / (1,011.64) 50.89%
Lam 3.38%  0.83% 3.83%  0.38% 3.78%  0.55% (9.63) 14.69% (24.03) 3.66% (148.37) 22.63%
Ram / 3.52%  0.38% 3.91%  0.74% / (89.23) 14.26% (299.32) 47.84%
Lhi 4.09%  0.00% 4.27%  0.35% 5.58%  1.79% (3.95) 0.25% (60.73) 3.87% (175.56) 11.19%
Rhi / 5.64%  0.58% 5.98%  1.42% / (85.02) 5.29% (283.03) 17.60%
L = Low-CAP; M = Mid-CAP; H = High-CAP. Keys: Lcaud, Left caudate; Rcaud, Right caudate; Lpal, Left globus pallidus; Rpal, Right globus pallidus; Ltha,
Left thalamus; Rtha, Right thalamus; lam, Left amygdala; ram, Right amygdala; Lhi, Left hippocampus; Rhi, Right hippocampus. A symbol “/” denotes no
significant group difference.
TABLE 5 The mean and standard deviations of the degrees of voxel-wise surface atrophy, restricted to each subregion of the bilateral caudate,
and the area (in mm2) of the vertices exhibiting significant atrophy and the area ratio (in %) of the vertices exhibiting significant atrophy to the
entire subregion obtained from the first test
Atrophy degree Atrophy area
C vs. L C vs. M C vs. H C vs. L C vs. M C vs. H
Left caudate Limbic 5.17%  0.74% 7.41%  1.92% 12.30%  4.52% (101.14) 23.56% (413.34) 96.29% (429.26) 100%
Executive 5.05%  0.98% 6.94%  1.60% 11.61%  4.06% (516.89) 53.84% (828.67) 86.31% (778.18) 81.05%
Rostral motor 5.09%  0.83% 8.24%  0.39% 12.15%  4.55% (13.46) 39.48% (34.09) 100% (34.09) 100%
Caudal motor 5.89%  0.40% 7.29%  0.80% 9.37%  4.36% (14.60) 9.73% (120.47) 80.30% (105.34) 70.21%
Parietal 5.08%  0.00% 6.34%  1.00% 7.89%  3.06% (3.46) 1.12% (228.00) 73.89% (176.43) 57.18%
Occipital / / / / / /
Temporal 5.18%  1.43% 6.10%  1.83% 9.48%  4.59% (14.37) 22.64% (63.44) 100% (59.60) 93.94%
Right caudate Limbic 4.69%  0.66% 8.07%  1.83% 13.92%  4.18% (171.90) 43.03% (399.51) 100% (399.51) 100%
Executive 4.59%  0.57% 7.87%  2.17% 12.98%  4.81% (269.43) 27.23% (886.12) 89.57% (850.31) 85.95%
Rostral motor / 7.75%  0.12% 12.73%  4.47% / (5.50) 100% (5.50) 100%
Caudal motor / 6.91%  0.94% 10.10%  3.41% / (96.65) 81.18% (101.44)85.20%
Parietal 5.17%  0.19% 6.45%  10.82% 8.49%  2.95% (8.86) 2.67% (273.24) 82.37% (286.61) 86.41%
Occipital / / / / / /
Temporal / 6.42%  1.96% 10.43%  4.05% / (34.34) 100% (34.34) 100%
L = Low-CAP; M = Mid-CAP; H = High-CAP. A symbol “/” denotes no significant group difference.
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variable involvement of other structures (globus pallidus, thalamus,
amygdala, and hippocampus) in mid-CAP and high-CAP participants.
These results are consistent with previous longitudinal studies indicat-
ing a temporal gradient of atrophy, with very early involvement of the
striatum and variable involvement of other structures with disease
progression.
Keeping in line with our volume analysis results, for all structures
exhibiting significant shape differences in the first test (Equation (1)),
we did not observe any significant interaction effects between the
clinical status and the aging effect from our second hypothesis testing
(Equation (2)). As such, we conclude that the reported group differ-
ences, in terms of both volume and shape, were induced more by the
disease pathology but not the aging effect.
4 | DISCUSSION
We conducted volume analysis and regional subcortical shape analysis
on a large sample of participants with premanifest HD compared with
controls. Low-CAP participants are estimated by statistical algorithm
to be relatively far from predicted manifest disease onset, high-CAP
participants are assessed to be relatively close to predicted manifest
disease onset, and mid-CAP participants are intermediate in their
distance from predicted manifest disease onset. Subregional abnor-
mality patterns were characterized for caudate, putamen, thalamus,
hippocampus, and amygdala.
According to the results observed from this study, the shape
deformation based morphometry measures are more sensitive to the
TABLE 6 The mean and standard deviations of the degrees of voxel-wise surface atrophy, restricted to each subregion of the bilateral putamen,
and the area (in mm2) of the vertices exhibiting significant atrophy and the area ratio (in %) of the vertices exhibiting significant atrophy to the
entire subregion obtained from the first test
Atrophy degree Atrophy area
C vs. L C vs. M C vs. H C vs. L C vs. M C vs. H
Left putamen Limbic 4.07%  0.55% 6.48%  1.54% 12.01%  2.66% (8.61) 2.54% (319.26) 94.31% (338.53) 100%
Executive 3.14%  0.00% 6.85%  1.12% 13.50%  2.00% (5.13) 0.97% (523.33) 99.33% (526.86) 100%
Rostral motor 2.23%  0.15% 6.56%  1.36% 13.28%  2.52% (10.14) 4.60% (220.21) 100% (220.21) 100%
Caudal motor / 5.69%  0.99% 11.88%  1.83% / (56.21) 100% (56.21) 100%
Parietal 3.76%  0.28% 5.93%  1.38% 11.07%  3.36% (14.79) 3.19% (355.66) 76.62% (464.17) 100%
Occipital / 5.33%  1.38% 10.64%  1.51% / (106.95) 100% (106.95) 100%
Temporal / 6.03%  1.20% 11.29%  2.02% / (20.16) 100% (20.16) 100%
Right putamen Limbic 3.99%  0.61% 6.60%  2.05% 12.34%  3.18% (62.63) 17.66% (334.14) 94.22% (354.63) 100%
Executive 3.56%  0.24% 6.22%  1.25% 12.89%  2.26% (17.79) 3.44% (517.32) 100% (517.32) 100%
Rostral motor / 6.69%  1.34% 12.76%  2.55% / (205.35) 100% (205.35) 100%
Caudal motor / 6.19%  1.32% 12.62%  2.82% / (124.33) 100% (124.33) 100%
Parietal 3.96%  0.44% 5.96%  1.58% 11.27%  3.29% (12.04) 2.83% (367.86) 86.41% (425.73) 100%
Occipital / 5.46%  1.34% 9.41%  1.69% / / (124.91) 100%
Temporal / 5.88%  0.82% 10.34%  1.45% / (34.71) 100% (34.71) 100%
L = Low-CAP; M = Mid-CAP; H = High-CAP. A symbol “/” denotes no significant group difference.
TABLE 7 The mean and standard deviations of the degrees of voxel-wise surface atrophy, restricted to each subregion of the bilateral thalamus,
and the area (in mm2) of the vertices exhibiting significant atrophy and the area ratio (in %) of the vertices exhibiting significant atrophy to the
entire subregion obtained from the first test
Atrophy degree Atrophy area
C vs. L C vs. M C vs. H C vs. L C vs. M C vs. H
Left thalamus Primary motor / 3.84%  0.00% 6.71%  1.81% / (4.45) 3.40% (67.46) 51.46%
Sensory / / 5.34%  1.27% / / (39.92) 56.44%
Occipital / 3.91%  0.21% 5.64%  1.82% / (6.25) 1.83% (149.02) 43.70%
Pre-frontal / 4.06%  0.37% 6.98%  2.44% / (32.17) 8.00% (240.71) 59.86%
Pre-motor / / 6.63%  1.34% / / (55.39) 45.85%
Posterial parietal / / 5.12%  1.36% / / (202.51) 75.67%
Temporal / / 6.28%  2.59% / / (319.22) 46.10%
Right thalamus Primary motor / / 5.81%  0.94% / / (45.94) 55.87%
Sensory / / 5.19%  1.46% / / (52.81) 56.93%
Occipital / / 6.67%  1.92% / / (113.06) 49.09%
Pre-frontal / / 6.22%  2.04% / / (249.38) 73.62%
Pre-motor / / 5.60%  1.41% / / (118.71) 66.46%
Posterial parietal / / 5.72%  1.45% / / (66.01) 36.46%
Temporal / / 6.42%  2.31% / / (365.71) 41.37%
L = Low-CAP; M = Mid-CAP; H = High-CAP. A symbol “/” denotes no significant group difference.
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neuropathology of premanifest HD than the conventional volume
measures. Given that MRI morphometry may be used as a primary
surrogate endpoint in clinical trials in premanifest HD and that pre-
manifest HD is a rare disease, being able to do trials with a sensitive
and robust measure that allows a smaller number of samples would be
advantageous.
This study is the first of its kind to investigate amygdala shape
morphometrics in premanifest HD. A majority of previous imaging
studies focused on basal ganglia structures, especially the striatum,
with some studies assessing the thalamus and hippocampus.
The estimated temporal evolution of regional and subregional
atrophy may be useful in assessing whether progression of pathology
in HD follows circuit-related patterns (Ross et al., 2014). Noncell
autonomous mechanisms such as the trans-synaptic spread of prion-
like protein aggregates, altered transport or effect of neurotrophic
factors such as BDNF or excitotoxicty are suggested as possible
mechanisms of cell-to-cell spread of neurodegeneration in HD and
other disorders (Pecho-Vrieseling et al., 2014; Surmeier, Obeso, &
Halliday, 2017). These hypothesized mechanisms predict that evolu-
tion of pathology should be related to anatomic connectivity.
All subcortical structures studied were affected in premanifest
HD, though the estimated timing of atrophy onset varied from struc-
ture to structure. Subcortical shape abnormalities were increased with
increasing CAP scores. Our findings are consistent with those of
previous studies focusing on HD-induced subcortical shape abnormal-
ities (Faria et al., 2016; Van den Bogaard et al., 2011; Younes et al.,
2014b), with some exceptions. In the work of Van den Bogaard
et al. (2011), the hippocampal and amygdalar shape abnormalities
were detected only in patients with manifest HD and not those with
premanifest HD. We conjecture that this indicates higher sensitivity
in our shape analysis pipeline, though other methodological differ-
ences may have contributed to some degree; differences, for example,
in automated segmentation approach (FSL-FIRST vs. MALF) and shape
analysis pipeline (GAMEs vs. diffeomorphometry).
Consistent with prior results, we found striatal changes in low-
CAP patients, primarily in the caudate. The putaminal changes were
manifest in mid-CAP participants and those changes appeared to
progress relatively rapidly with marked atrophy in high-CAP partici-
pants. Meanwhile, other regions (globus pallidus, thalamus, hippocam-
pus, amygdala) had detectable atrophy at the mid-CAP stage with
worsening atrophy detected in high-CAP participants.
Subregional analyses of the caudate and putamen revealed early
atrophy in subregions connected to the limbic and executive–function
related cortices. It is important to note that our analysis did not
include the caudate tail, which is described as an early site of neurode-
generation in HD (Vonsattel et al., 1985). Our caudate and putamen
results are consistent with cognitive and behavioral changes described
in premanifest HD participants (Ille et al., 2011; Kloppel et al., 2010;
TABLE 8 The mean and standard deviations of the degrees of voxel-wise surface atrophy, restricted to each subregion of the bilateral amygdala,
and the area (in mm2) of the vertices exhibiting significant atrophy and the area ratio (in %) of the vertices exhibiting significant atrophy to the
entire subregion obtained from the first test
Atrophy degree Atrophy area
C vs. L C vs. M C vs. H C vs. L C vs. M C vs. H
Left amygdala Basolateral / 4.27%  0.00% 4.20%  0.49% / (5.27) 4.47% (31.72) 26.91%
Basomedial / / 3.71%  0.32% / / (39.34) 20.95%
Centramedial 3.38%  0.25% 3.66%  0.00% 3.44%  0.55% (9.63) 7.66% (3.53) 2.80% (37.52) 29.81%
Lateral nucleus / 3.79%  0.40% 3.94%  0.55% / (15.23) 6.80% (39.80) 17.76%
Right amygdala Basolateral / 3.45%  0.39% 3.89%  0.63% / (26.26) 23.20% (90.46) 79.92%
Basomedial / 3.74%  0.06% 3.84%  0.64% / (5.13) 3.02% (74.99) 44.11%
Centramedial / 3.457%  0.39% 4.25%  0.88% / (51.68) 39.63% (92.00) 70.55%
Lateral nucleus / 3.15%  0.16% 3.46%  0.56% / (6.17) 2.91% (41.88) 19.74%
L = Low-CAP; M = Mid-CAP; H = High-CAP. A symbol “/” denotes no significant group difference.
TABLE 9 The mean and standard deviations of the degrees of voxel-wise surface atrophy, restricted to each subregion of the bilateral
hippocampus, and the area (in mm2) of the vertices exhibiting significant atrophy and the area ratio (in %) of the vertices exhibiting significant
atrophy to the entire subregion obtained from the first test
Atrophy degree Atrophy area
C vs. L C vs. M C vs. H C vs. L C vs. M C vs. H
Left hippocampus CA1 / / 7.51%  1.12% / / (7.06) 1.16%
CA2 4.09%  0.00% 4.27%  0.39% 5.16%  1.34% (3.95) 1.52% (34.24) 13.14% (65.21) 25.03%
CA3/DG / 4.50%  0.39% 6.34%  1.78% / (9.22) 4.88% (57.11) 30.22%
Subiculum / 4.14%  0.29% 4.70%  2.01% / (17.27) 3.38% (46.17) 9.05%
Right hippocampus CA1 / 5.53%  0.40% 5.87%  0.58% / (17.35) 2.76% (33.21) 5.29%
CA2 / 5.05%  0.88% 5.06%  1.07% / (8.41) 4.14% (31.48) 15.48%
CA3/DG / / 6.31%  1.58% / / (115.98) 50.40%
Subiculum / 5.76%  0.58% 5.94%  1.47% / (59.25) 10.85% (102.37) 18.74%
L = Low-CAP; M = Mid-CAP; H = High-CAP. A symbol “/” denotes no significant group difference.
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Lawrence et al., 1996; Lemiere, Decruyenaere, Evers-Kiebooms,
Vandenbussche, & Dom, 2004; Misiura et al., 2017; Petersen &
Gabery, 2012) and plausibly reflect dysfunction of frontostriatal cir-
cuits (Tziortzi et al., 2014; Wolf et al., 2007).
The globus pallidus findings from this study are consistent with
our prior imaging study, namely the extent of atrophy in high-CAP
participants was greater in lateral than medial pallidum (Reiner et al.,
2012; Richfield & Herkenham, 1994; Younes, Ratnanather, et al.,
2014b), a likely correlate of the preferential loss of striato-lateral palli-
dal neurons found in post-mortem studies (Albin et al., 1992; Deng
et al., 2004; Sapp et al., 1995).
The changes in the globus pallidus and thalamus at higher CAP
scores might be consistent with evolution of pathology following ana-
tomically defined connections. Major striatal outputs synapse within the
two segments of the globus pallidus (and the substantia nigra). HD is
characterized by a preferential loss of projections to the lateral globus
pallidus, the site of the greatest pallidal atrophy in our analyses. This
result could be consistent with preferential loss of lateral globus pallidus
neurons as predicted by a circuit-based spread of pathology. The palli-
dum, however, has a relatively low density of neurons and pallidal atro-
phy may also reflect the substantial loss of striatal afferents and fibers
of passage. Our subregional shape analysis results revealed that the tha-
lamic subregions connecting to pre-frontal cortices and temporal lobe
were affected the most. Basal ganglia outputs from the pallidum and
substantia nigra pars reticulata innervate the mediodorsal, ventral ante-
rior, and ventrolateral thalamic nuclei. These thalamic nuclei are densely
connected to prefrontal cortices and our results could partially reflect
atrophy of thalamic nuclei intimately linked to the striatum.
On the other hand, these basal ganglia associated thalamic nuclei
are not connected to the temporal lobe and our shape analysis indi-
cates significant atrophy in thalamic subregions connected to tempo-
ral cortices, something that would not be explained easily by a circuit
based model of pathology progression. Some components of medial
and anterior thalamic nuclei that project to temporal cortices, how-
ever, are closely adjacent to and may overlie thalamic subregions pro-
jecting to frontal cortices (Behrens et al., 2003). It is possible that
atrophy of mediodorsal/ventral anterior subregions receiving basal
ganglia inputs might result in a deformation of closely adjacent and
overlying subregions projecting to temporal cortices.
Subregional shape analysis of the hippocampus and amygdala
were featured in several studies investigating AD (Apostolova et al.,
2010; Miller et al., 2013; Tang et al., 2014; Tang, Holland, Dale,
Younes, Miller, et al., 2015; West, Kawas, Martin, & Troncoso, 2000).
By contrast, we believe this study is the first for HD. Vertices belong-
ing to hippocampal and amygdala subregions exhibited changes in pre-
manifest HD. The CA2 and CA3/DG subregions of the hippocampus
seemed to be more affected than other subregions, with the changes
occurring in the lowest CAP scores in CA2. In the amygdala, the cen-
tromedial subregion was affected in mid-CAP participants with atro-
phy involving other regions occurring only in high-CAP participants.
These results are distinct from findings in AD, where basolateral amyg-
dala and CA1 were found to be most affected (Tang et al., 2014; Tang,
Holland, Dale, Younes, Miller, et al., 2015; West et al., 2000).
Our findings are relevant to the question of whether progression
of pathology in HD follows a noncell autonomous “circuit” pattern
(Ross et al., 2014). Our analysis of changes in the basal ganglia and thal-
amus may be at least in part consistent with this model. As discussed
above, striatal deformation changes were found in the low-CAP score
participants and apparently followed by changes in the pallidum and
thalamus, which are hodologically downstream from the striatum.
Our results for the hippocampal and amygdala changes, however,
appear inconsistent with a simple circuit based spreading model. In
these structures, deformation changes were found in mid-CAP partici-
pants in CA2 of the hippocampus and centromedial amygdala. Neither
of these regions are strongly connected to the dorsal striatum. While
the striatum receives afferents from both the hippocampal formation
and amygdala, these projections terminate mainly in the ventral stria-
tum, which appears to be relatively spared in HD (Vonsattel et al.,
1985). In addition, CA2 is primarily part of the intrinsic circuitry of the
hippocampus and consequently, a less likely candidate as a recipient of
spreading pathology from other regions. Similarly, the centromedial
amygdala is primarily an output structure, receiving input from other
amygdala nuclei and projecting to hypothalamic and brainstem
structures (Benarroch, 2015). Overall, thus our results are only partially
consistent with a simple spreading model of HD pathology, and also
suggest the possibility of multiple foci of cell autonomous
neurodegeneration.
Our hippocampal and amygdala results suggest some potentially
interesting clinical correlations. The pattern of hippocampal changes is
distinct from prior results in AD, and memory dysfunction in AD and
HD are clearly different. The centromedial amygdala is felt to be a key
node in the regulation of social behaviors, and apathy, irritability, and
socially inappropriate conduct are commonly seen in premanifest HD
and early manifest HD. Dysfunction of social behavior networks
involving the medial amygdala are implicated in Tourette syndrome
and tics are commonly observed phenomenon in HD patients (Albin,
2017). The observation that emotional changes are less consistent in
premanifest HD (Investigators of the Huntington Study Group
PHAROS, 2006) compared with cognitive and motor changes is con-
sistent with the pattern of brain changes—striatum at lowest CAP
scores, and amygdala at higher CAP scores.
Finally, we note that even in high-CAP participants, there are
regions of the thalamus, amygdala, and hippocampus exhibiting no
shape abnormalities. It is plausible that at least some of these rela-
tively spared subregions will atrophy with disease progression, proba-
bly during the manifest HD stage. To confirm this, study of patients in
the later phases of HD are required. To understand the causal rela-
tionship between the progression of pathology in HD and the trajec-
tories of subcortical shape atrophy, prospective longitudinal studies
will be necessary. Understanding the temporal progression patterns of
HD and its correlated effects on the morphometry of the subcortical
structures and their associated subregions with prospective longitudi-
nal data is something we anticipate as a future endeavor.
One limitation of this study is that it was limited to subcortical
structures but not cortical regions which are also involved in the pro-
gression of premanifest HD. The reasons were twofold: (1) We cur-
rently do not have a fully validated approach to automatically
segment cortical regions. (2) The shape analysis approaches for sub-
cortical and cortical regions should be different. One of our future
research directions is to resolve this issue, extending the shape
1430 TANG ET AL.
analysis pipeline employed in this work to various cortical regions.
Another future work is to investigate the associations between sub-
cortical regional shape abnormalities and different clinical measures in
premanifest HD. Detailed descriptions of the clinical phenotypes in
PREDICT-HD can be found elsewhere (Misiura et al., 2017).
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